Abivax SA American Depositary Shares

Abivax SA American Depositary Shares

Yahoo Finance • 7 days ago

Abivax Rebounds, but Obefazimod Unlikely to Replace JAK Inhibitors, Wedbush Says

Abivax (ABVX) shares have rebounded to pre-Phase 3 maintenance data levels as investor concerns over PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 12 days ago

Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares

Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares Upsized offering increased from the previously announced $600M to $800M at $125.00 per ADS, priced at a 2.39% premiu... Full story

Yahoo Finance • 12 days ago

ABIVAX Announces Pricing Of $800 Mln Offering Of ADS

(RTTNews) - Wednesday, ABIVAX Société Anonyme (ABVX) announced the pricing of an underwritten public offering of 6.4 million American Depositary Shares or ADSs, each representing one ordinary share, 0.01 nominal value per share, of the com... Full story

Yahoo Finance • 12 days ago

Here Are Wednesday’s Best Wall Street Analyst Research Calls: Abbott Laboratories, Circle Internet, Dow, Kratos Defense, Lockheed Martin, Salesforce, ServiceNow,SpaceX, and More

Quick Read All four major U.S. indices posted their best first-half performances in years, but stocks enter Q3 overbought with the Magnificent 7 underperforming. Citigroup upgraded LMT to Buy with a $582 target, while Guggenheim raised bo... Full story

Yahoo Finance • 12 days ago

Abivax Requests Trading Halt On Euronext Paris For $600 Mln ADS Offering

(RTTNews) - Abivax SA (ABVX, ABVX.PA), a clinical-stage biotechnology company, announced on Wednesday that trading of its shares on the Euronext Paris market will be temporarily halted, at the company's request, from the opening of the mar... Full story

Yahoo Finance • 12 days ago

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 07:30 a.m. CEST –Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology co... Full story

Yahoo Finance • 13 days ago

Abivax stock jumps on positive Phase 3 ulcerative colitis data

[Female Scientist Performing A Scientific Experiment In A Laboratory, Holding A Petri Dish And Dropper.] Tashi-Delek * Abivax SA (ABVX [https://seekingalpha.com/symbol/ABVX]) shares surged Tuesday premarket after the biotech reported [h... Full story

Yahoo Finance • 26 days ago

ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm

LOS ANGELES, June 17, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abivax S.A. (“Abivax” or “the Company”) (NASDAQ: ABVX)... Full story

Yahoo Finance • last month

European Value Stocks Trading Below Estimated Intrinsic Values June 2026

As European markets navigate a period of uncertainty marked by economic contractions and fluctuating retail sales, investors are increasingly focused on identifying opportunities that offer attractive valuations. In this context, finding s... Full story

Yahoo Finance • last month

High Growth Tech Stocks To Watch In The Global Market

Global markets have been buoyed by optimism surrounding a potential U.S.-Iran peace agreement, with major U.S. stock indexes like the Nasdaq Composite and Russell 2000 reaching record highs, driven in part by enthusiasm for AI-linked stock... Full story

Yahoo Finance • last month

Abivax Grounded as Cancer Cases Cast a Shadow Over Best-in-Class Trial Data

Abivax Grounded as Cancer Cases Cast a Shadow Over Best-in-Class Trial Data - Moby THE GIST Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Ta... Full story

Yahoo Finance • last month

Here Are Tuesday’s Top Wall Street Analyst Research Calls: CoreWeave, Danaher, Hewlett Packard Enterprise, Intuit, Knight-Swift, Meta Platforms, Starwood Property Trust, Tripadvisor, and More

Quick Read: Stocks started the week where they left off Friday, with all the major indices except the Russell 2000 closing higher. The S&P 500, looking to post its 10th consecutive week of gains, once again closed at an all-time high on M... Full story

Yahoo Finance • last month

Abivax Phase 3 Obefazimod In Ulcerative Colitis Shows Maintenance Benefit; Shares Fall

(RTTNews) - Abivax SA (ABVX) has reported pivotal Phase 3 ABTECT Maintenance trial, evaluating Obefazimod in adults with moderately to severely active ulcerative colitis. Ulcerative colitis is a chronic inflammatory bowel disease that cau... Full story

Yahoo Finance • last month

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis At Week 44, both the 25 mg and 50 mg once-daily obefazimod doses met the primary endpoint, demons... Full story

Yahoo Finance • last month

Abivax annonce des résultats majeurs de l’essai de maintenance de phase 3 ABTECT évaluant l’obéfazimod dans le traitement de la rectocolite hémorragique active modérée à sévère

Abivax annonce des résultats majeurs de l’essai de maintenance de phase 3 ABTECT évaluant l’obéfazimod dans le traitement de la rectocolite hémorragique active modérée à sévère À la semaine 44, les deux doses d’obéfazimod, 25 mg et 50 mg... Full story

Yahoo Finance • 2 months ago

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors

Key Points Saturn V sold 1,504,880 shares of Ocular Therapeutix in the first quarter; the estimated transaction value was $14.34 million. Meanwhile, the quarter-end position value declined by $18.27 million, reflecting both share sales an... Full story

Yahoo Finance • 2 months ago

Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?

Key Points Initiated 1,446,375-share position in Beam Therapeutics; estimated trade size $40.13 million (quarterly average price). Quarter-end stake valued at $34.47 million, a net position change reflecting both trading and price movemen... Full story

Yahoo Finance • 2 months ago

Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy?

Key Points ADAR1 Capital Management added 829,963 shares of Crinetics Pharmaceuticals; estimated trade size $37.07 million based on quarterly average pricing. Quarter-end position value increased by $26.98 million, reflecting both trading... Full story

Yahoo Finance • 2 months ago

Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish

Octagon Capital Advisors cut its stake in Dianthus Therapeutics(NASDAQ:DNTH) by 470,000 shares, an estimated $27.22 million trade based on quarterly average pricing, according to a May 15, 2026 SEC filing. What happened According to a SE... Full story

Yahoo Finance • 2 months ago

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares

On May 15, 2026, HighVista Strategies disclosed it sold 70,503 shares of Maze Therapeutics(NASDAQ:MAZE) in Q1 2026, an estimated $3.11 million trade based on quarterly average pricing. What happened According to a Securities and Exchange... Full story